Caplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura.[4][5][6] It is a von Willebrand factor-directed antibody fragment.[4] It is given via intravenous injection followed by subcutaneous injection.[4] Caplacizumab was developed by Ablynx NV.
Caplacizumab was authorized for medical use in the European Union in August 2018,[7] and approved for medical use in the United States in February 2019.[8]
Caplacizumab is indicated for the treatment of acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy.[4][7][11]
Common adverse effects include injection site reactions, reported in 3–6% of patients in the HERCULES and TITAN trials.[12]
Caplacizumab was authorized for medical use in the European Union in August 2018,[7] and approved for medical use in the United States in February 2019.[8][11]
The cost-effectiveness has been questioned.[13]
Caplacizumab is the international nonproprietary name[14] and the United States Adopted Name.[15]
Use of caplacizumab without plasmapheresis has been reported.[16] The MAYARI study was designed to evaluate the effectiveness of this option.[17]
